MET and non-small cell lung carcinoma: Capmatinib has also been evaluated in combination with gefitinib in patients with EGFR-mutant NSCLC who progressed on previous gefitinib treatment, the overall ORR was 27%, while strong antitumor activities were seen in patients with high MET-amplified tumors (ORR47%) [28].